Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
GSBR-2657
- Development stage
- Preclinical
- Lead developer
- Structure Therapeutics
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
GSBR-2657 is an investigational, orally available small molecule agonist of the glucagon-like peptide-1 receptor (GLP-1R) developed by Structure Therapeutics. In preclinical studies, GSBR-2657 has demonstrated high binding affinity to human GLP-1R and potent activation of the Gαs-cAMP pathway. In humanized GLP-1R mouse models, oral administration of GSBR-2657 showed dose-dependent glucose clearance, reduced food intake, and significant body weight loss comparable to semaglutide. It is being investigated as a potential treatment for type 2 diabetes and obesity.
02
Targets
Beyond the preview
Go deeper on GSBR-2657.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GSBR-2657.